2024 Tom Isaacs Award honours Parkinson’s expert Professor Oliver Bandmann
Cure Parkinson’s and Van Andel Institute (VAI) are delighted to announce Professor Oliver Bandmann as the winner of the 2024 Tom Isaacs Award, which honours researchers who closely collaborate with the Parkinson’s community.
The award was virtually presented to Professor Bandmann as part of the annual Grand Challenges in Parkinson’s Disease symposium and parallel Rallying to the Challenge meeting for people living with Parkinson’s held in Grand Rapids, Michigan in September. Professor Bandmann said:
I was absolutely delighted to receive the Tom Isaacs Award. I remember Tom well – he was incredibly inspirational. However, I would like to acknowledge that this award really reflects the excellence of Parkinson’s research across the Sheffield Neuroscience community. I’m also very lucky to work together with such wonderful clinical colleagues in our Sheffield Teaching Hospitals Movement Disorders Service.
Watch Professor Oliver Bandmann receive the award
Professor Bandmann is Professor of Movement Disorders Neurology and Co-Director of the Cross-Faculty Neuroscience Research Institute at University of Sheffield, UK. His research is focused on discovering new treatments with the potential to slow, stop or reverse Parkinson’s. Professor Bandmann’s research group screened a library of 2000 compounds in patient tissue to identify promising compounds, including ursodeoxycholic acid (UDCA), a drug already in use to treat liver disease. Work by Professor Bandmann suggests UDCA may also address mitochondrial dysfunction in Parkinson’s models. The team were able to take UDCA to clinical trial at phase 2, and results were positive; the trial met its primary outcome and showed UDCA to be safe and well tolerated, with participants on the drug showing consistent improvement of gait. UDCA is now moving forward to the next stage of clinical testing.
Professor Bandmann also investigates non-motor symptoms of Parkinson’s, particularly the common symptom of pain. He is widely published, with eight articles in the prestigious journal Brain alone.
Professor Bandmann is a clear example of the very essence of the Tom Isaacs award, which was set up in memory of Cure Parkinson’s late co-founder and President. The award recognises a researcher who has significantly impacted the lives of people living with Parkinson’s and has involved people with Parkinson’s in a participatory way in their work. Professor Bandmann runs two movement disorders clinics every week and is the Movement Disorders Service Lead at Sheffield Teaching Hospitals, a role through which he has worked to improve the service for patients and training for Parkinson’s nurses. Under his leadership, a regional shared care protocol for Parkinson’s drugs was developed and implemented across South Yorkshire which has dramatically simplified and standardised the availability of primary care drugs for Parkinson’s.
As a National Neurosciences Advisory Group (NNAG) Lead for two years, Professor Bandmann took on feedback from public and patient consultations. He worked to develop a new pathway which emphasised the importance of a timely and well managed diagnosis for people with Parkinson’s and other movement disorders, and subsequent regular access to healthcare professionals. He worked to improve accessibility for people with Parkinson’s, encouraging healthcare providers to embrace novel ways of working such as digital monitoring and remote appointments where appropriate.
Professor Bandmann also served as the President of the Doncaster branch of Parkinson’s UK, and has been involved in several awareness raising and community outreach campaigns.
Helen Matthews, CEO of Cure Parkinson’s said:
We are thrilled to present the Tom Isaacs Award for 2024 to Oliver. He and his team are breaking new ground in the search for disease-modifying treatments for Parkinson’s, and he has consistently worked to improve the care received by those diagnosed with the condition. We are delighted to celebrate Oliver’s passion and commitment to the Parkinson’s community with this thoroughly deserved award.